VigiLanz alternatives and competitors for antimicrobial stewardship, AUR reporting and antibiograms

VigiLanz competitors compared

Each product is described only from its vendor's public pages and product overviews, read in September 2026. Where a vendor does not say something publicly, the table says so instead of guessing. Antimicrobe is not affiliated with Inovalon, Wolters Kluwer, Premier, BD or Epic.

The VigiLanz tiers, and where the antibiogram sits

Understanding the tiers is most of the decision, because the alternative you need depends on which one you are on. Inovalon's May 2026 Starter overview describes a web-based product for small and critical access hospitals that aggregates data from the EHR, lab and pharmacy systems, validates it, and submits AU and AR data to NHSN in the HL7 CDA format. Its dashboards show facility-wide and unit-level metrics such as days of therapy and proportion susceptible. It does not describe a cumulative antibiogram, and it is explicitly positioned as the tier you start on before upgrading.

The base Pharmacy Surveillance tier for acute care adds near real-time alerts, prioritized worklists, rounding tools, and antibiotic alerts for drug-bug mismatches, missed therapies and de-escalation. The Pro overview adds opioid stewardship, IV-to-PO conversion tracking, medication reconciliation, alerts delivered inside the EHR, and, in Inovalon's words, analytics and antibiograms to visualize usage, resistance and outcomes. So a hospital on Starter or the base tier that wants the antibiogram from VigiLanz is buying Pro.

• Starter: AUR collection, validation and NHSN submission, dashboards. For small and critical access hospitals.
• Pharmacy Surveillance: alerts, worklists, rounding, antibiotic use alerts. For acute care.
• Pro: everything above plus IV-to-PO, medication reconciliation, EHR-embedded alerts, on-demand and trending antibiogram data.
• Ambulatory Surveillance: a separate outpatient product for interactions, duplicate therapy and missed labs.

Sentri7, if you want the current KLAS leader

Sentri7 is the most direct like-for-like replacement. Wolters Kluwer's stewardship page describes real-time alerts, IV-to-oral tracking, SAAR benchmarking, one-click NHSN AUR submission that is NHSN-validated and ONC-certified, and an antibiogram produced from its dashboard. It took both the pharmacy surveillance and the infection control and monitoring segments in the 2026 Best in KLAS report. Like VigiLanz it is one module of a broader platform, called SoleSource, with drug diversion, infection prevention and opioid stewardship alongside, so a hospital that only uses stewardship should ask for single-module pricing before comparing quotes.

We cover the reverse decision on the Sentri7 alternatives and competitors page, and all three large platforms side by side in Sentri7 vs TheraDoc vs VigiLanz.

TheraDoc and BD HealthSight, if the platform matters more than the tier

Premier's clinical surveillance product, powered by TheraDoc, leads on real-time stewardship alerts, automated NHSN reporting tools, EHR-interfaced data, and coverage of both acute and post-acute settings. That post-acute coverage is the clearest reason to prefer it for a health system that also runs skilled nursing beds. The product page does not mention an antibiogram, so ask to see one printed, with its de-duplication rule and isolate threshold, before assuming it replaces the VigiLanz Pro report.

BD HealthSight Clinical Advisor is described as house-wide antimicrobial stewardship using data from the EMR, order entry, lab and pathology systems, with a companion Infection Advisor with MedMined Insights for infection surveillance. BD's page talks about comparing regional and national resistance data rather than a facility antibiogram. It is the natural choice where BD dispensing and pharmacy analytics are already in the building.

The TheraDoc competitors and alternatives page has the fuller comparison, and the BD side, including Infection Advisor, is covered on MedMined and BD HealthSight alternatives.

Staying inside Epic instead

For an Epic hospital the alternative to any third-party surveillance product is building the work in the EHR. Epic's certification page lists Bugsy Infection Control as certified for antimicrobial use and resistance reporting, so leaving VigiLanz does not mean losing AUR. The worklists, alerts and antibiogram are builds, and published hospital experience from Johns Hopkins in 2021 describes that as needing stewardship physicians, pharmacists and Epic IT staff with significant time. The trade is a license fee for analyst hours, and the antibiogram is usually the last item to reach the top of that queue.

KLAS's 2026 report on Epic Bugsy is worth reading before you make that move. As summarized by HealthSystemCIO in February 2026, Bugsy scored 80.6 overall, VigiLanz infection control scored 90.8 and was the third-party product most often paired with Bugsy, and organizations that moved from VigiLanz or BD to Bugsy reported lower satisfaction afterward. Many Epic hospitals keep VigiLanz beside Bugsy for that reason.

The full KLAS picture, and when replacing Bugsy or running a platform beside it makes sense, is in Epic Bugsy alternatives.

Keep VigiLanz Starter and buy the antibiogram separately

Antimicrobe is not a VigiLanz replacement and this page does not present it as one. It does not fire near real-time alerts, does not submit AU or AR data to NHSN, does not track IV-to-PO conversions, and has no opioid or medication reconciliation module. If your pharmacists work the VigiLanz queue every morning, or Starter is submitting your AUR data cleanly, keep it.

What it does is the cumulative antibiogram, built the way CLSI M39 describes. You export finalized susceptibility results from the LIS as a CSV. The builder keeps the first isolate per patient, marks cells under 30 isolates, applies a named breakpoint set, cuts by unit, specimen source and quarter, counts MDRO phenotypes, and ranks empiric options by local percent susceptible. Every rule is printed on the report, which is what a P and T committee asks for and what a dashboard antibiogram often leaves off.

That gives a Starter customer a third option beyond upgrading to Pro or leaving. Keep Starter for NHSN AUR, and cover the antibiogram from the same lab export for a published $249 a month on the Lab plan. A Pro customer at renewal can make the same move in reverse: keep the alerts on whichever platform wins the evaluation and take the annual antibiogram off the platform so it stops depending on an interface.

The full list of what is and is not included is on the antimicrobial stewardship software features page, and our guide to antibiotic stewardship software for critical access hospitals covers the 25-bed case that Starter is sold to.

• Replaces: the hand-built annual antibiogram, unit and source cuts, quarterly trends, the committee pack
• Does not replace: near real-time alerts, NHSN AUR submission, IV-to-PO tracking, opioid stewardship, medication reconciliation
• Runs alongside: VigiLanz Starter, base or Pro, Sentri7, TheraDoc, BD HealthSight or Epic, from the same lab data

What to check before you leave VigiLanz

The risk in switching is not the new software. It is the gap between systems. Each of these is worth confirming in writing before notice is given.

• AUR continuity: which system submits AU and AR data to NHSN for each month of the CMS reporting period, with no uncovered months
• Rules: how many custom VigiLanz rules you run, and who rebuilds them in the next system
• Intervention history: whether pharmacist interventions and documentation export in a format the next platform can load
• Add-ons: whether NINJA nephrotoxicity monitoring or DoseMeRx dosing sit on the same contract and need a replacement
• Interfaces: realistic build time for ADT, eMAR, lab and microbiology feeds, in your own IT hours
• Contract: the notice period, the auto-renewal date, and the price of staying on a lower tier

Who should stay on VigiLanz

Stay if your stewardship pharmacists work its alerts daily, if Starter is submitting your AUR data without trouble, if your hospital already runs other Inovalon products and the contract reflects that, or if the Pro antibiogram is used and trusted by your committee. A product that held the KLAS pharmacy surveillance segment for years is a poor thing to replace to fix one report. In that case keep it, and fix the report.